Home›Trial›NCT07431866
🔬NCT07431866Phase 1RECRUITING

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Study Summary

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Conditions
Healthy
Interventions / Drugs
RosuvastatinFurosemideMK-2828
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment39 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.206410+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.